RxDoctor Payments Data

Anas Salih, MD

Internal Medicine · Flint, MINPI 1508251539

Payments from drug & device makers

$1,090in general payments, 2019–2025

Across 64 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$248
  • Amgen$207
  • Novo Nordisk$72
  • Otsuka America Pharmaceutical, Inc.$59
  • Vanda Pharmaceuticals Inc.$52
  • Axsome Therapeutics, Inc.$49
  • plus $403 from 19 others

What the payments were for

  • Food & beverage$1,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,090 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$68,235
Medicare patients
184
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$134,375
VumerityDiroximel Fumarate11$110,541
JardianceEmpagliflozin84$74,123
EliquisApixaban80$59,267
TrulicityDulaglutide46$57,268
JanuviaSitagliptin Phosphate46$35,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$21,178
MounjaroTirzepatide20$20,471
Repatha SureclickEvolocumab23$15,280
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$13,054
XareltoRivaroxaban14$10,287
Tresiba Flextouch U-100Insulin Degludec18$9,567
SymbicortBudesonide/Formoterol Fumarate34$8,073
Novolog FlexpenInsulin Aspart18$5,967
Breo ElliptaFluticasone/Vilanterol12$5,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$72$134,375108 claims
Lilly USA, LLCTrulicity, Mounjaro$41$77,73966 claims
Boehringer IngelheimJardiance$43$74,12384 claims
GSKTrelegy Ellipta, Breo Ellipta$12$26,80543 claims
AstraZenecaSymbicort, Brilinta$28$13,48045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →